Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aflibercept every 2 months · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| aflibercept every 2 months | EXPERIMENTAL | - |
| aflibercept monthly | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Aflibercept every 2 months | DRUG | 2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10) |
| Aflibercept monthly | DRUG | 2.0mg aflibercept intravitreal injections every month (M0-11) |
Inclusion Criteria: * Retinopathy associated with previous I-125 brachytherapy for uveal melanoma (85 Gy over 96 hours) at least 6 months prior to enrollment * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \> 18 years * Center...
Aflibercept every 2 months is used for radiation retinopathy, a condition that can cause macular edema. It is administered via intravitreal injection and is being studied in the ophthalmology therapeutic area. The drug is a small molecule developed by Regeneron Pharmaceuticals.
Aflibercept every 2 months is developed by Regeneron Pharmaceuticals, Inc., which trades under the ticker REGN. The company is conducting clinical research on this drug for the treatment of radiation retinopathy.
Aflibercept every 2 months is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The drug has received a priority review designation from the FDA, indicating it is being evaluated for expedited review.
Aflibercept every 2 months has one completed clinical trial, NCT01579760, titled "Intravitreal Aflibercept Injection for Radiation Retinopathy." This Phase 1 trial enrolled 9 participants in the United States and studied the drug's effects on radiation retinopathy and macular edema.
Aflibercept every 2 months is a dosing regimen of aflibercept, a medication that blocks vascular endothelial growth factor (VEGF). The every 2 months schedule refers to the frequency of administration, which is being evaluated in clinical trials for radiation retinopathy.